Neurokinin receptors in the central nervous system are involved in the neural circuitry of anxiety, depression and emesis. This has led to the development of nonpeptidic NK1 receptor antagonists as therapeutic agents. Clinical trials have shown that NK1 receptor antagonists have efficacy in chemotherapyinduced emesis and depression. Sequence polymorphisms can potentially influence the efficacy of drugs in patient populations and are an important consideration in the drug development process. To identify DNA sequence variants in the NK1 receptor, comparative DNA sequencing was performed on a population of 93 individuals. In total, 19 single-nucleotide polymorphisms (SNPs) were identified with one SNP (g.78351T4C) resulting in a tyrosine to histidine subsitution at residue 192 (Y192H). The Y192H variant was expressed using site-directed mutagenesis and was characterized with respect to affinity, receptor kinetics, functional calcium response and receptor internalization. In all cases the Y192H variant was found to display properties similar to those of the wild-type receptor.
INTRODUCTION
Substance P (SP) is a member of the neurokinin family of peptides, which includes neurokinin A (NKA) and neurokinin B (NKB). These peptides exert their biological effects by acting at their respective G-protein coupled receptor (GPCR); neurokinin-1 receptor (NK-1R), neurokinin-2 receptor (NK-2R) and neurokinin-3 receptor (NK-3R). 1 Recently, hemokinin-1 (HK-1) has been identified as a new member of the neurokinin family of peptides. Although a novel receptor for HK- 1 has not yet been identified, HK-1 has been shown to posses affinity and selectivity for the tachykinin receptors that is nearly identical to SP. NK1 antagonist, aprepitant (MK869, Emend), is an approved treatment for chemotherapy-induced emesis. 7, 8 Sequence polymorphisms in genes that encode receptors, phase I and phase II metabolizing enzymes, and drug transporters have the potential to affect many aspects of drug efficacy, metabolism and safety. Recent advances including the availability of the complete human genome sequence have raised interest in sequence variability with regard to the investigational and clinical development of new drugs. Early studies were directed toward identifying polymorphisms in enzymes that are involved in drug metabolism and pharmacokinetic variability. More recently, the focus has shifted to include alterations in drug target genes. 9 Polymorphisms affecting drug sensitivity have been suggested in inositol polyphosphate-1-phosphatase (INPP1), 10 the b2-adrenoceptor (ADRB2) 11 and the serotonin 2A receptor (5HTR2A). 12 Identification of polymorphisms that affect efficacy and adverse event susceptibility have the potential to impact selection of patient populations, dosage and formulation. 13 Therefore, early application of pharmacogenetics to the drug development process is likely to improve clinical trial design and patient safety. The US Food and Drug Administration recently recognized the increased activity in this area when it issued a draft guidance in November 2003 regarding submission of these data in regulatory filings.
In this study, we report identification of sequence variants in the NK1 receptor. Several examples demonstrate that small changes in receptor sequence can have profound effects on receptor function and ligand affinity. For example, a single amino-acid difference between rat and human NK1 receptors is responsible for a greater than 100-fold affinity discrepancy for several small molecule antagonists.
14 If a coding region single nucleotide polymorphism (SNP) resulted in an amino acid change that conferred similar effects, efficacy of NK1 antagonists in individuals with that SNP would be expected to be reduced. To investigate this possibility, we conducted a detailed pharmacological characterization of the NK1 receptor variant that resulted from a sequence polymorphism.
RESULTS

Genetic Variations of the Human NK1 Receptor Gene
The human NK1 receptor consists of a 1221 nucleotide open reading frame (ORF) divided into five exons spanning 150 kilo base pairs on 2p13.1-p12. Resequencing of the NK1 ORF, 5 0 and 3 0 UTR's and an average of 100 bp upstream and downstream flanking the intron/exon splice junctions from an anonymous panel of Caucasian (n ¼ 46) and AfricanAmerican (n ¼ 47) subjects identified 19 SNPs (Table 1) . Three SNPs were identified within the protein-coding region of the gene, one of which (g.78351T4C) resulted in an amino-acid substitution (Y192H). This novel genetic variation occurred in Exon 2 of the gene at a position corresponding to the c-terminal portion of the second extracellular loop (E2) adjacent to transmembrane domain (Figure 2 ).
The EC 50 values for intracellular calcium efflux in response to the NK1 agonist GR-73632 were determined using FLIPR and found to be nearly identical for both Table 2 Kinetic parameters for wild type and Y192H variant human NK1 receptors Table 4 are from nonlinear regression rather than Scatchard analysis.
receptors. K b values determined by Schild analysis of NK1 antagonist-mediated inhibition of the calcium response did not differ significantly between WT and Y192H NK1 receptors ( Figure 3 ).
Agonist-induced receptor internalization of the wild-type and mutant receptors was examined for differences in the rate or degree of internalization. Bodipy labeled substance P (25 nM) was used to trace the receptors from cell surface binding through formation of endosomes. No differences were observed in the rate or quantity of endosome formation in COS-7 cells expressing the wild type or Y192H forms of the receptor when treated with labeled substance P ( Figure 4 ).
DISCUSSION
This is the first report of polymorphisms in the human neurokinin NK1 receptor gene. Sequencing of the coding regions and intron/exon boundaries led to the identification of 19 SNPs in the NK1 receptor from a sample of 93 Caucasian and African-American individuals. Of these 19 SNPs, 16 localized to noncoding regions and two of the three located in exons were silent. One SNP, g.78351T4C, causes a missense mutation at Y192H corresponding to the carboxyl-terminal portion of the second extracellular loop (E2), adjacent to TM-V. This polymorphism was observed only in the African-American population (2%), 13/19 (66%) SNPs identified in this study were observed only in the African-American population examined. These data are consistent with other published reports of large-scale SNP identification studies 15, 16 demonstrating a greater degree of nucleotide diversity in African American compared to Caucasian populations. The sample size used in this study was sufficiently powered to insure identification of at least 99% of all SNPs present in either population at a minor allele frequency of 5% or greater. 16 The protocols used to identify the majority of SNPs present in public SNP databases, including dbSNP (http://www.ncbi.nlm.nih.gov/SNP), used significantly fewer samples. 17 This helps to explain why 16/ 19 (84.2%) of SNPs described here have not been previously reported.
Studies using chimeric receptors and point-mutations have identified two residues in close proximity to the SNP, E193 and H197, which have been reported to be important for agonist and antagonist affinity, respectively. [18] [19] [20] While secondary structure predictions have not identified H197 as Results are expressed as the Mean (7SEM) from three or more independent transfections.
Single-nucleotide polymorphisms of the NK1 receptor GP Randolph et al a critical determinant for ligand binding, and mutagenesis studies of H197 have not been reported, subtle changes in the interactions between residues in the binding pocket might be expected by substituting an aromatic side chain with a side chain containing an imidazole ring. However, it was found that hNK1Y192H does not differ significantly from the wild-type receptor with respect to agonist or antagonist binding.
As we have previously shown that HK1 is a high-affinity agonist at NK1 receptors, 2 we investigated HK1 binding to NK1Y192H. However, no differences in affinities were observed. The fact that HK1 and SP have nearly identical binding properties is consistent with what has already been determined about this peptide in prior studies with wildtype receptor.
Despite a lack of differences between the agonist and antagonist affinities for the two receptors, changes in the kinetics of association and dissociation might still have resulted from the amino-acid substitution. Therefore, association and dissociation experiments were performed to address this possibility. The results of these experiments showed no significant shift in on-or off-rates between the mutant and wild-type forms. Based on the results of the experiments discussed thus far, it is reasonable to assume that the direct binding of pharmacophores to their respective NK1 receptor epitopes would not be impacted by the 574T4C allele. In addition, the efficacy and potency of the NK1 agonist GR73632 to induce intracellular calcium mobilization were found to be nearly identical for both receptors. The potency of NK1 antagonist to inhibit this response was also not affected by the mutation. A well-studied characteristic of NK1 receptors is rapid agonist-induced internalization. 21 While the SNP discussed here is not found in the cytoplasmic space, we sought to determine whether the mutant receptor possesses the proper signaling and trafficking capabilities required to execute this function in a normal manner. The extent of substance Pinduced receptor internalization did not significantly differ between the wild-type and mutant receptors indicating normal receptor trafficking function. These internalization experiments also served as an indirect measure of receptor signaling, as only receptors with appropriate coupling would be expected to initiate endocytotic processes.
Reports have shown that poor response to drug therapy and increased susceptibility to adverse drug reactions can result from genetic variability in patient populations. It has thus become apparent that identification of these subpopulations is important to the development and clinical evaluation of pharmacological agents. The investment of time and resources for the development and clinical evaluation of new drugs necessitates a closer examination of not only the candidate compounds but also the biological target and its associated pathways. 22 A large amount of study into genetic variation of enzymes involved in drug metabolism has already been conducted. Mutations of cytochrome P450 enzymes and their role in adverse side effects and nonresponse have been well documented. [23] [24] [25] More recently, investigations have begun to focus on polymorphisms of target proteins, their promoters and signaling pathways. A polymorphism in the promoter of the gene ALOX5 has been linked to a reduced clinical response to the lipoxygenase inhibitor ABT-761 in asthma patients. 26 In another study, a mutation (825C4T) in the gene for the b3 subunit of G protein (GNB3) has been shown to result in enhanced coronary vasoconstriction upon a2 adrenoceptor activation by BHT 933, a specific a2 receptor agonist. 27 The need to identify and understand allelic variation has been of particular concern in the treatment of psychotic and affective disorders where a high percentage of nonresponders are observed. Numerous studies suggest that allelic variations are at least partly responsible for variability in efficacy. Arranz et al 12 suggest that polymorphisms of the 5-HT 2A receptor affect response to clozapine in patients with schizophrenia. In other studies, polymorphisms in the promoter of the serotonin transporter gene (5-HTT) have been suggested to impact the efficacy of fluvoxamine and paroxetine. 28, 29 Many more studies have been conducted with these and other targets in this disease area. As the NK1 receptor has become an important potential target for the treatment of affective disorders, identification and study of genetic variation in the NK1 receptor were conducted with the objective of providing some benefit to ongoing or future clinical investigation of this target. Our studies with a novel coding region NK1 receptor SNP did not reveal any alterations in the examined pharmacological properties of the NK1 receptor. Therefore, this polymorphism is not likely to require special consideration in the development of pharmaceutical agents that target the NK1 receptor.
MATERIALS AND METHODS
SNP Identification Research subjects
To identify SNPs, the NK1 receptor gene was sequenced from anonymous Caucasian (n ¼ 46) and African-American (n ¼ 47) individuals. Genomic DNA samples were obtained from the Caucasian and African-American Human Variation Panels collected by the Human Genetic Cell Repository of the National Institute for General Medical Sciences (Coriell Cell Repository; Camden, NJ, USA). All samples came from individuals who provided informed consent to be part of the DNA Polymorphism Discovery Resource. Information on geographic origin and gender was collected for each individual in order to assemble the DNA Polymorphism Discovery Resource, but all identifying and phenotypic information has been removed from the individual samples.
Polymerase chain reaction
SNP identification was conducted according to the strategy previously described by Nickerson, 30 with slight modifications. PCR primers (see Table 4 for PCR primer sequences, annealing temperature and predicted amplicon size) were designed using the Primer3 software (http://www.genome. wi.mit.edu/cgi-bin/primer/primer3.cgi) to amplify NK1 0 TGTAAAACGACGGCCAGT and M13REV; CAG-GAAACAGCTATGACC, respectively. PCR reactions contained genomic DNA (24 ng) in the presence of Platinum PCR Supermix ((100 mM dNTPs, 1.5 mM MgCl 2 , 0.l U Platinum Taq polymerase) (Life Technologies/Invitrogen Corp; Carlsbad, CA, USA)) and 0.2 pmol/ml forward and reverse primers in a 12 ml total volume. Thermocycling was performed in 96-well microplates on a PTC-200 thermocycler (MJ Research; Waltham, MA, USA) with an initial denaturation at 941C for 5 min followed by 35 cycles of denaturation at 941C for 30 s, primer annealing for 30 s, and primer extension at 721C for 1 min. After 35 cycles, a final extension was carried out for 7 min at 721C.
DNA sequencing and analysis
Following DNA amplification, PCR reactions were diluted to a final concentration of 1.0 ng/ml in deionized water. Cycle sequencing in the forward and reverse directions was performed using ABI PRISM BigDye Primer Cycle Sequencing DNA Sequencing Kits À21M13 and M13Rev, respectively (Applied Biosystems; Foster City, CA, USA) according to the manufacturer's instructions. Sequencing reactions were denatured for 1 min at 961C followed by 15 cycles at 961C for 10 s, 551C for 5 s and 701C for 1 min and 15 cycles at 961C for 10 s and 701C for 1 min. Individual A, C, G and T reactions were subsequently pooled, purified by ethanol precipitation, resuspended in 10 ml deionized water and resolved by capillary gel electrophoresis on a 3700 DNA Analyzer (Applied Biosystems; Foster City, CA, USA). Chromatograms were transferred to a Unix workstation (DEC alpha, Compaq Corp; Palo Alto, CA, USA), base called with Phred (version 0.990722.g), assembled with Phrap (version 3.01) scanned with Polyphred (version 3.5) 31 and the results viewed with Consed (version 9.0) (Phred, Phrap and Consed available at http://www.genome.washington.edu, PolyPhred is available at http://droog.mbt.washington.edu). Analysis parameters were all maintained at the individual software's default settings. SNPs were named according to the convention described by Antonarakis 32 referenced from the genomic sequence with reference base 1 corresponding to the A in the initiating methionine codon (position 75400596 of the human genome working draft July 2003 freeze http://genome.ucsc.edu/cgi-bin/hgGateway).
Point mutation and cloning
Vector pCI-neo containing wild-type human NK1 receptor (hNK1 wt ) cDNA between the T7 and T3 promoters was supplied by Washington University (St Louis, MO, USA). The desired mutation (g.78351T4C) was introduced by PCR in a single reaction using the Quick Change site-directed mutagenesis kit (Stratagene; La Jolla, CA, USA). The primers used to introduce the point mutation were 5 0 GCATCCGAACAAGATTCATGAGAAAGTGTACC and GTA-CACTTTCTCATGAATCTTGTTCGGATGC (the underlined sequences indicate the changed bases for nucleotide 574). Plasmids were purified from cultures of individual transformants using the QIAprep spin miniprep kit (Qiagen Sciences, Valencia, CA, USA) and screened by XhoI/XbaI digestion. Six plasmid preparations contained the single point mutation, as confirmed by DNA sequencing of the entire hNK1Y192H insert. The insert was excised by XhoI/ XbaI digestion, gel purified and inserted into fresh pCI-neo expression vector for subcloning. The plasmid was transiently transfected into COS-7 cells (ATCC; Manassas, VA, USA) and membrane preparations or whole cells were used in subsequent experiments.
Pharmacological Characterization Competitive binding
All assays were performed in 96-well plates in a 200 ml final volume. 50 mM Tris HCl, pH 7.5 buffer containing 1 mM Binding and saturation assays were incubated for 40 min at room temperature. Association assays were incubated for 40 min (max time point), while the dissociation assays were incubated for 1 h (max time point) at room temperature. All assays were terminated by vacuum filtration using a cell harvester (Brandel; Gaithersburg, MD, USA) over GF/B filter plates (Perkin-Elmer; Boston, MA, USA) presoaked in 0.3% polyethylenamine. Filter plates were washed with ice-cold 50 mM Tris HCl, pH 7.5, dried and, following addition of Microscint 20 scintillation cocktail (Packard Bioscience; Meriden, CT, USA), the bound radioactivity was determined in a Topcount scintillation counter (Packard Bioscience; Meriden, CT, USA).
For data analysis of competition binding, nonlinear regression analysis was determined using XLfit (IDBS, Surrey, UK). These were converted to K i values based upon predetermined affinity (K d ) determinations using the method of Cheng-Prusoff (1973 
Calcium mobilization
Cells were collected and approximately 70 000-100 000 cells per well were seeded onto poly-D-lysine coated 96-well plates (BioCoat #4640, clear, flat-bottom with black-wall, Becton Dickinson; Bedford, MA, USA). The plates were then incubated at 371C, 5% CO 2 overnight. The media were aspirated and 100 ml of a loading media (Hanks BSS with 20 mM HEPES, 1% BSA, 4 mM Fluo-3-AM (Molecular Probes; Eugene, OR, USA) in 0.4% pluronic acid and 2.5 mM Probenecid) was added and the plates were incubated at 371C, 5% CO 2 for 60 min. Compounds were prepared at three times the final concentration (150 ml final volume) for pretreatment and the agonist at four times the final concentration (200 ml final volume). All drugs were diluted so that the final DMSO concentration was 1.25%. The Fluorescence Imaging Plate Reader (FLIPR, Molecular Devices; Sunnyvale, CA, USA) was setup to pretreat the cells for 10 min with antagonist, then measure the stimulation of intracellular calcium after the addition of the agonist GR-73632 (RBI/Sigma; St Louis, MO, USA). The effect of the agonist alone on calcium stimulation was also monitored for maximal response. Endogenous SP (RBI/Sigma; St Louis, MO, USA) and hemokinin-1 (Tocris; Ellisville, MO, USA) were used as agonist in single addition assays to compare the response of transfected cells to these agonists.
Calcium was measured by the fluorescence emitted by Fluo-3-AM (l ex ¼ 485 nm, l em ¼ 520 nm). GraphPad PRISM was used to determine the IC 50 of the agonist in the absence and presence of antagonist using nonlinear regression analysis. The K b of the antagonist was then determined using the method of Schild 34 based on dose-ratios obtained in the presence of a number of antagonist concentrations and compared to the affinity obtained using competition binding.
Receptor internalization
Transfected cells were grown on poly-D-lysine coated glass coverslips to 80-90% confluence. Growth media were aspirated and cells were washed with two changes of Buffer (Earles Balanced Salt Solution containing 200 mM Tris, pH 7.4, 0.2% BSA, 0.01% Glucose, 10 mM MgCl 2 , 1 mM MnCl 2 and protease inhibitors (Complete, Roche Diagnostics GmbH; Mannheim, Germany). Cells were pre-incubated with fresh buffer at 41C or 371C for 20 min. Buffer was removed and replaced with buffer containing 25 nM Bodipy 576/589 Substance P (BDSP) (Perkin-Elmer; Boston, MA, USA) in the presence or absence of CP-99,994. Cells were incubated at 371C for 60 min and then washed for 1 min in ice cold buffer. A duplicate set of cells was incubated at 41C for baseline internalization determinations. Cells were washed with ice cold buffer, fixed in 4% paraformaldyhyde, thoroughly rinsed in dH 2 O and mounted with VectaShield (Vector Labs; Burlingame, CA, USA) on slides.
BDSP treated cells were examined at 400 fold magnification on a DMIRBE microscope with a TCS SP multiband confocal imaging spectrophotometer (Leica Microsystems; Bannockburn, IL, USA). Laser excitation was at 566 nm and emission was observed by photomultiplier tube between 578 and 700 nm. Digital images were the compiled average of eight individual scans through a single focal plane (Leica Confocal Software).
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